8-K: Cardiff Oncology Reports Strong Phase 2 Data, 2025 Results

Cardiff Oncology announced positive full-year 2025 financial results and compelling Phase 2 CRDF-004 trial data for onvansertib in RAS-mutated mCRC, supporting advancement to registrational development.

Summary

• Reported full-year 2025 financial results and a business update.
• Positive update from the Phase 2 CRDF-004 trial in first-line RAS-mutated metastatic colorectal cancer (mCRC).
• The 30 mg onvansertib + FOLFIRI/bev arm achieved a confirmed objective response rate (ORR) of 72.2% compared to 43.2% for combined standard of care (SoC) arms.
• Demonstrated marked improvement in progression-free survival (PFS) versus FOLFIRI/bev (HR: 0.38) and combined SoC (HR: 0.37, p<0.05), with no significant added toxicity.
• Plans to advance the 30 mg onvansertib dose with FOLFIRI/bev into a registrational program.
• Detailed data and registrational plans are expected in the first half of 2026 after discussions with the FDA.
• Cash, cash equivalents, and short-term investments totaled approximately $58.3 million as of December 31, 2025.
• Existing cash resources are sufficient to fund operations into the first quarter of 2027.
• Total operating expenses for 2025 were approximately $49.6 million, a slight increase from $49.3 million in 2024.
• Net loss for 2025 was $45.851 million, compared to $45.431 million in 2024.
• Mani Mohindru, PhD, was appointed interim Chief Executive Officer in January 2026.
• Brigitte Lindsay was promoted to Chief Accounting Officer in January 2026.
• A search for a permanent Chief Executive Officer and Chief Financial Officer has been initiated.
• Investigator-sponsored Phase 1 trial data for onvansertib monotherapy in chronic myelomonocytic leukemia (CMML) showed preliminary efficacy in approximately 40% of patients.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive update driven by compelling Phase 2 clinical data that significantly outperforms standard of care in a high unmet need indication, providing a clear path to registrational studies despite ongoing leadership transitions and future financing needs.

Positives

• Robust Objective Response Rate (ORR) of 72.2% in the 30 mg onvansertib + FOLFIRI/bev arm, significantly higher than the 43.2% for combined standard of care (SoC) arms in first-line RAS-mutated mCRC.
• Significant improvement in Progression-Free Survival (PFS) with a Hazard Ratio (HR) of 0.37 (p<0.05) over combined SoC, indicating a substantial delay in disease progression.
• No significant added toxicity observed with the onvansertib combination, suggesting a favorable safety profile.
• Data supports the selection of the 30 mg onvansertib dose for a planned registrational program, providing a clear path forward for the lead asset.
• Existing cash resources of $58.3 million are sufficient to fund operations into the first quarter of 2027, providing a runway for upcoming clinical milestones.
• Preliminary efficacy observed in an investigator-sponsored Phase 1 trial of onvansertib monotherapy in chronic myelomonocytic leukemia (CMML), validating potential activity across hematologic and solid tumors.

Negatives

• Net loss increased slightly to $45.851 million in 2025 from $45.431 million in 2024.
• Cash and cash equivalents decreased from $51.470 million in 2024 to $17.470 million in 2025.
• Total current assets decreased from $95.054 million in 2024 to $60.128 million in 2025.
• The company is actively searching for a permanent Chief Executive Officer and Chief Financial Officer, indicating ongoing leadership transition.

Risks

• Clinical trials are lengthy, expensive, and have uncertain outcomes, and results of earlier studies and trials may not be predictive of future trial results.
• Clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks, potentially precluding product candidate approval.
• Results of preclinical studies or clinical trials for the product candidate could be unfavorable or delayed.
• Need for additional financing in the future.
• Risks related to business interruptions, including the outbreak of COVID-19 coronavirus and cyber-attacks on information technology infrastructure, which could seriously harm financial condition and increase costs and expenses.
• Uncertainties of government or third-party payer reimbursement.
• Dependence on key personnel.
• Limited experience in marketing and sales.
• Substantial competition in the oncology space.
• Uncertainties of patent protection and litigation.
• Dependence upon third parties for various aspects of development and operations.
• Risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations.
• No guarantees that the product candidate will be utilized or prove to be commercially successful.
• No guarantees that future clinical trials will be completed or successful or that the product candidate will receive regulatory approval for any indication.

Future Outlook

Cardiff Oncology plans to advance the 30 mg dose of onvansertib with FOLFIRI/bev into a proposed registrational program for first-line RAS-mutated mCRC. Detailed Phase 2 CRDF-004 data and registrational plans are expected in the first half of 2026, following discussions with the FDA. The company believes its existing cash resources are sufficient to fund operations into the first quarter of 2027.

Management Comments

• Cardiff Oncology has entered 2026 with strong clinical momentum and a clear path for advancing onvansertib, our lead program, in first-line RAS-mutated metastatic colorectal cancer.
• Our focus in 2025 was on rigorous clinical execution, which allowed us to generate increasingly compelling evidence supporting onvansertib's potential to improve patient outcomes in RAS-mutated mCRC, culminating in the latest positive data cut announced earlier this year.
• The CRDF-004 trial demonstrated a consistent, dose-dependent treatment benefit when onvansertib was added to FOLFIRI/bev, including a near 30% improvement in response rate over the control arm and encouraging durability trends as measured by progression-free survival.
• Given that it has been over two decades since there has been meaningful innovation for this patient population, we believe these results represent a transformative step forward.
• Based on these results, we plan to advance the 30 mg dose of onvansertib with FOLFIRI/bev into our proposed registrational program and expect to provide detailed data and registrational plans after discussions with the FDA in the first half of 2026.
• As we transition into late-stage clinical development and continue to strengthen our leadership and operational teams, we remain focused on disciplined execution, progressing our lead program toward a potential new standard of care in first-line RAS-mutated mCRC.

Industry Context

StockSavvy.ai notes that the positive Phase 2 CRDF-004 trial results for onvansertib in first-line RAS-mutated mCRC are highly significant, especially given the stated lack of meaningful innovation in this patient population for over two decades. This positions onvansertib as a potential breakthrough therapy in a high unmet need area within oncology, potentially disrupting the current standard of care and offering a new treatment paradigm for a challenging cancer subtype.

Comparison to Industry Standards

• The filing explicitly states, "it has been over two decades since there has been meaningful innovation for this patient population," highlighting a significant unmet need and positioning onvansertib as a potential leader in this specific mCRC segment.
• The 72.2% ORR for onvansertib + FOLFIRI/bev compares favorably to the 43.2% ORR of combined standard of care (SoC) arms (FOLFOX/bev and FOLFIRI/bev), demonstrating a substantial improvement over existing treatments.
• The Progression-Free Survival (PFS) Hazard Ratio (HR) of 0.37 (p<0.05) against combined SoC suggests a clinically meaningful extension of time without disease progression, which is a critical endpoint in oncology trials.

Management Changes

Stakeholder Impact

• Shareholders: Potential for significant value appreciation due to highly positive clinical trial results and a clear path to registrational studies for a drug targeting a high unmet medical need. However, future dilution from capital raises is a possibility.
• Patients: Significant positive impact for patients with first-line RAS-mutated metastatic colorectal cancer, as onvansertib offers a potentially transformative new treatment option with superior efficacy and comparable safety to existing standard of care.
• Employees: Leadership changes indicate a strategic shift towards late-stage development, potentially bringing new opportunities and challenges. The search for permanent CEO/CFO suggests ongoing organizational evolution.
• Regulatory Authorities (FDA): The company's plans for discussions with the FDA in H1 2026 indicate active engagement towards regulatory approval, which could streamline the path to market if successful.

Next Steps

• Advance the 30 mg dose of onvansertib in combination with FOLFIRI/bev into planned registrational development.
• Share detailed Phase 2 CRDF-004 data in the first half of 2026.
• Provide registrational plans for onvansertib in combination with FOLFIRI/bev in first-line RAS-mutated mCRC in the first half of 2026, after discussions with the FDA.
• Continue the search for a permanent Chief Executive Officer and Chief Financial Officer.
• Strengthen leadership and operational teams to support late-stage clinical development.

Key Dates

Recommendation

The compelling Phase 2 CRDF-004 trial data, demonstrating a robust 72.2% ORR and significant PFS improvement (HR: 0.37, p<0.05) with no added toxicity in first-line RAS-mutated mCRC, represents a transformative step forward in an area with over two decades of limited innovation. This strong clinical efficacy, coupled with a clear plan for registrational development and sufficient cash runway into Q1 2027, positions Cardiff Oncology for substantial growth. While leadership transitions and future financing needs exist, the clinical breakthrough potential outweighs these factors, making it a strong buy for investors seeking exposure to high-impact oncology innovation.

Keywords

Cardiff Oncology, CRDF, Onvansertib, PLK1 inhibitor, RAS-mutated mCRC, Metastatic Colorectal Cancer, Phase 2 Trial, CRDF-004, Objective Response Rate, Progression-Free Survival, FOLFIRI/bev, Oncology, Biotechnology, Clinical-stage, FDA discussions, Registrational program, CMML, Financial Results 2025